Clinical Efficacy and Safety in Telbivudine- or Tenofovir-Treated Hepatitis B e Antigen-Positive Pregnant Women
暂无分享,去创建一个
Min Xu | Huiyuan Liu | Hongbo Gao | L. Zhuo | Haohui Deng | Keng Chen | Y. Lei | Shuzhen Liang | Yuming Shi | Huihui Li | Qian Jiao | Liansheng Lin
[1] Caixia Zheng,et al. Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy , 2019, Medicine.
[2] Feng Chen,et al. Epidemiological trends and virological traits of hepatitis B virus infection in pregnant women and neonates , 2019, Archives of Virology.
[3] L. Touqui,et al. Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads , 2018, Scientific Reports.
[4] B. Liao,et al. Naturally occurring antiviral drug resistance in HIV patients who are mono‐infected or co‐infected with HBV or HCV in China , 2018, Journal of medical virology.
[5] H. Deng,et al. Quasispecies characters of hepatitis B virus in immunoprophylaxis failure infants , 2018, European Journal of Clinical Microbiology & Infectious Diseases.
[6] Wan-Hsin Wen,et al. Management of Pregnant Women and Children: Focusing on Preventing Mother-to-Infant Transmission , 2017, The Journal of infectious diseases.
[7] D. Zhang,et al. Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother‐to‐child transmission of hepatitis B virus , 2017, Journal of viral hepatitis.
[8] H. Tang,et al. Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long‐term follow‐up , 2017, Journal of viral hepatitis.
[9] Thomas Berg,et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.
[10] Fei-Long Huang,et al. Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load , 2017, Scientific Reports.
[11] Ariel Jaffe,et al. A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women. , 2017, Gastroenterology & hepatology.
[12] Shuqin Zhang,et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. , 2016, The New England journal of medicine.
[13] Mei-Hwei Chang,et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother‐to‐infant transmission of hepatitis B virus , 2015, Hepatology.
[14] D. Sahota,et al. Age-specific prevalence of hepatitis B virus infection in young pregnant women, Hong Kong Special Administrative Region of China , 2014, Bulletin of the World Health Organization.
[15] M. Dal,et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. , 2013, World journal of gastroenterology.
[16] J. Jia,et al. Update on epidemiology of hepatitis B and C in China , 2013, Journal of gastroenterology and hepatology.
[17] Yang Ding,et al. Chronic HBV infection among pregnant women and their infants in Shenyang, China , 2013, Virology Journal.
[18] Chin-peng Lee,et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. , 2013, Journal of hepatology.
[19] Wei Zhao,et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. , 2011, Journal of hepatology.
[20] J. Preiksaitis,et al. Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants , 2011, Journal of viral hepatitis.
[21] Y. Liaw,et al. Efficacy and safety of prolonged 3‐year telbivudine treatment in patients with chronic hepatitis B , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[22] D. Harnois,et al. Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B , 2011 .
[23] T. Tran,et al. Management of chronic hepatitis B in pregnancy. , 2010, Clinics in liver disease.
[24] T. Berg,et al. Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues , 2010, Hepatology.
[25] Li Li,et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. , 2009, The Journal of infectious diseases.
[26] I. Serra,et al. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. , 2009, Antiviral research.
[27] F. Zoulim,et al. Hepatitis B virus genetic variability and evolution. , 2007, Virus research.
[28] Ding‐Shinn Chen,et al. Hepatitis B Virus Infection , 2007 .
[29] R. Burk,et al. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. , 1994, The Journal of infectious diseases.